Investing.com - IGM Biosciences (NASDAQ: IGMS) reported third quarter EPS of $-1.01, $0.21 worse than the analyst estimate of $-0.80. Revenue for the quarter came in at $520K versus the consensus estimate of $230.56K.
IGM Biosciences's stock price closed at $14.37. It is up 62.74% in the last 3 months and up 221.48% in the last 12 months.
IGM Biosciences saw 5 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See IGM Biosciences's stock price’s past reactions to earnings here.
According to InvestingPro, IGM Biosciences's Financial Health score is "fair performance".
Check out IGM Biosciences's recent earnings performance, and IGM Biosciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar